Dendrogenix SA
8.0 FTEThe score of Dendrogenix shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -6 % Total assets +16 % Headcount (avg FTE) -2 %
Accounts of the company itself (not consolidated).
The full file covers 7 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Dendrogenix's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 02 Jul 2026
- Year ended 31 Dec 2024filed on 20 Jun 2025
- Year ended 31 Dec 2023filed on 12 Jun 2024
- Year ended 31 Dec 2022filed on 09 May 2023
- Year ended 31 Dec 2021filed on 05 Jul 2022
Dendrogenix's financial analysis
- Solvency62.4%sector median: 57.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Dendrogenix
Dendrogenix's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0700.613.677
- VAT number
- BE0700613677
- Peppol
- Registered · 0208:0700613677 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 02 Aug 2018
- Registered office
- 4000 Liège
- Size
- Micro · 8.0 FTE
- Latest accounts
- 2025 · filed on 02 Jul 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Dendrogenix (SA) has been based in Liège since 2018, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of €2.29m and equity of €3.29m; its revenue is not published. With 8.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 62.4%, above the median of its sector (57.9%).
Companies similar to Dendrogenix
Companies in the same business, of comparable size and area, outside its group.
- H2WIN Research and experimental development on natural sciences and engineering Nivelles · balance sheet €7.36m
- APIX Biosciences Research and experimental development on natural sciences and engineering Wingene · balance sheet €5.89m
- Nexelis Europe Research and experimental development on natural sciences and engineering Charleroi · balance sheet €4.65m
- Celyad Oncology Research and experimental development on natural sciences and engineering Mont-Saint-Guibert · balance sheet €4.03m
- Novobiom Research and experimental development on natural sciences and engineering Liège · balance sheet €3.92m
- Alixar Research and experimental development on natural sciences and engineering Hasselt · balance sheet €18.5m
- Abaxys Therapeutics Research and experimental development on natural sciences and engineering Villers-la-Ville · balance sheet €1.31m
- ConvEyXo Research and experimental development on natural sciences and engineering Charleroi · balance sheet €10.3m
Frequently asked questions about Dendrogenix
What is the revenue of Dendrogenix?
Dendrogenix files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Dendrogenix?
In Belgium, the VAT number is the company number prefixed with BE: BE0700613677 for Dendrogenix, if the company is VAT-registered. Its company number (CBE) is 0700.613.677.
Where is the registered office of Dendrogenix?
According to the CBE register, the registered office of Dendrogenix is in 4000 Liège.
What is the equity of Dendrogenix?
At the close of the 2025 financial year, the equity of Dendrogenix amounts to 3,291,041 €, a solvency of 62.4% of total assets.
How many people work at Dendrogenix?
8.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Dendrogenix?
The register lists 12 active mandates at Dendrogenix. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Dendrogenix
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →